Hologic Receives Neutral Rating from Zacks (HOLX)
Hologic (NASDAQ:HOLX)‘s stock had its “neutral” rating restated by Zacks in a report released on Wednesday. They currently have a $26.00 target price on the stock. Zacks‘s target price would indicate a potential upside of 3.42% from the company’s current price.
Zacks’ analyst wrote, “Hologic posted an improved second-quarter fiscal 2014 with adjusted EPS of $0.37, up 7.9% year over year, which surpassed the Zacks Consensus Estimate by $0.04. The results also exceeded the company’s expectation. Revenues of $625 million were up 2% and exceeded the Zacks Consensus Estimate of $610 million. It also edged past the company’s guidance range. Amid looming headwinds such as lower sales of legacy products, a challenging capital spending environment, European uncertainty and increasing pricing pressure, Hologic’s topline was boosted by strong performance in the 3D tomosynthesis and MyoSure product lines. Currently, the major goal of management is to sustain top- and bottom-line organic growth going ahead. Besides, it is also working on the divesture of some of its smaller businesses to focus on the more profitable ones. Accordingly, we reiterate the stock at Neutral.”
A number of other firms have also recently commented on HOLX. Analysts at Needham & Company LLC raised their price target on shares of Hologic from $26.00 to $30.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Argus raised their price target on shares of Hologic from $27.00 to $31.00 in a research note on Monday, May 12th. They now have a “buy” rating on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hologic in a research note on Thursday, May 1st. They now have a $28.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $23.83.
Hologic (NASDAQ:HOLX) traded up 1.87% during mid-day trading on Wednesday, hitting $25.61. The stock had a trading volume of 1,939,466 shares. Hologic has a one year low of $18.46 and a one year high of $25.84. The stock has a 50-day moving average of $24.45 and a 200-day moving average of $22.36. The company’s market cap is $7.077 billion.
Hologic (NASDAQ:HOLX) last released its earnings data on Wednesday, April 30th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.04. The company had revenue of $625.00 million for the quarter, compared to the consensus estimate of $609.35 million. Analysts expect that Hologic will post $1.40 EPS for the current fiscal year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.